Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

He’s not sure when the second-year starter will be healthy enough to be cleared to play. Allen was placed in the NFL’s concussion protocol after taking a helmet-to-helmet hit by Patriots defensive back Jonathan Jones in the opening minute of the fourth quarter of a 16-10 loss to New England on Sunday. Putting aside the three interceptions Allen threw, McDermott’s biggest question was why Jones wasn’t ejected. “There’s no room in football for that,” McDermott said. “I thought he should have been thrown out. But other than that, I’m not going to get into that. That’s for the league to get into.” The hit occurred when Allen scrambled out of the pocket and burst through a hole up the middle while facing third-and-8 at the New England 45. He gained 7 yards before Jones closed in on him, lowered his helmet and struck the quarterback in the crown of his helmet. Jones was flagged for a personal foul for unnecessary roughness. Allen lay on the field for several minutes before hopping up on his own. He was briefly evaluated on the sideline before being escorted up the tunnel. Allen was spotted in the locker room chatting with teammates following the game. NFL officiating chief Al Riveron told a pool reporter the decision to not eject Jones came because the hit did not rise to the level of the league standard for disqualification. “There was a foul called and obviously the penalty stood, but we did not feel this contact rose to that level,” Riveron said, who also noted Jones was turning his head just before hitting Allen. Bills safety Micah Hyde questioned the official’s judgment saying he or any of his teammates would have been ejected for a similar hit on New England’s Tom Brady. “That’s our quarterback. We ride or die with him,” Hyde said. “To see that happen, Josh didn’t slide, but at the end of the day it doesn’t matter if you’re a running back, you can’t head to the head.” Jones defended the hit saying it was never his intent to hurt Allen. “No malice or intent. Just a part of football,” Jones said. “We’re just running around playing football. I hope he’s OK. I’m going to check on him.” Allen finished going 13 of 28 for 153 yards, and scored on a 1-yard touchdown dive. Allen’s uncertain status leaves Buffalo with veteran backup Matt Barkley the only quarterback on the active roster in preparing to play at Tennessee next weekend. Buffalo then enters its bye week. The loss prevented Buffalo (3-1) from getting off to its first 4-0 start since 2008. Though the Bills defense held Brady in check, their offense was busy coughing up the ball at critical moments for the third time in four games. Allen threw three interceptions, two of which translated into a touchdown and a field goal. Punter Corey Bojorquez also had a punt blocked by J.C. Jackson, which led to Matthew Slater returning it 11 yards for a touchdown to put the Patriots up 13-0 in the first quarter. McDermott was unhappy with Allen’s continuing string of committing turnovers. He’s now thrown six interceptions and lost two fumbles in four starts this season. “He’s a young quarterback and sometimes they have to learn those lessons. Those are hard lessons and we have to continue to coach it up,” McDermott said. The game was decided on Buffalo’s fourth turnover with 1:27 left. Facing third-and-9 on the New England 39, Barkley was pressured by linebacker Kyle Van Noy, who got his hand on the quarterback’s chest. That forced Barkley to throw the ball up into the air, and have it easily picked off by Jamie Collins. The loss spoiled a stout effort by a Bills defense which limited the Patriots to just 11 first downs and 224 yards. Brady finished 18 of 39 for 150 yards and an interception. He was picked off by Hyde in the end zone on third-and-goal from the 2 in the second quarter. Brady’s 45.9 passer rating was the sixth lowest of his career and lowest since finishing with a 34 rating in a 27-20 loss to Indianapolis on Nov. 5, 2006. Barkley lamented how the Bills let the Patriots off the hook. “Especially with the way our defense played and where we had the ball at the end of the game, it’s tough,” Barkley said. “This is a tough one.” ___ More AP NFL: https://apnews.com/NFL and https://twitter.com/AP_NFL
Bills fall to Pats, and lose QB Josh Allen to head injury.

Biotechnology company Alkermes said earlier in the day that  it expected Lilly to drop out of their program to develop an  inhaled insulin treatment for diabetes, sending Alkermes shares  down more than 9 percent. Lilly’s decision marks the third setback in recent months  for inhaled insulin formulations, once deemed potential  blockbuster products because of their greater convenience than  standard injectable insulin. Cambridge, Massachusetts-based Alkermes, which makes the  alcohol addiction drug Vivitrol, said Lilly has the right to  terminate its license to the inhaled treatment, Air Insulin, at  its discretion. “While Lilly may elect not to commercialize Air Insulin,  Alkermes believes that the phase 3 safety and efficacy trials  should be completed,” Alkermes said in a statement. After Lilly’s announcement, the company said it was  evaluating the impact of the termination, which will become  effective in 90 days. Indianapolis-based Lilly said its decision was not due to  safety concerns, “but rather was a result of increasing  uncertainties in the regulatory environment, and a thorough  evaluation of the evolving commercial and clinical potential of  the product compared to existing medical therapies.”    Lilly Chief Operating Officer John Lechleiter said in a  statement that the company is beginning the process of halting  ongoing clinical studies. Lilly said it will record a first-quarter 2008 charge of  around $90 million to $120 million, or 5 cents to 7 cents per  share. The company said its adjusted earnings per share outlook  remains unchanged at $3.85 to $4.00, while net earnings will  range from $3.73 to $3.90. Lilly’s action comes just five months after Pfizer Inc  abandoned Exubera, the first approved inhaled form of insulin,  and returned rights to the product to longtime partner Nektar  Therapeutics. Exubera had dismal sales because patients were turned off  by the clumsy device used to administer the powdered insulin  and because doctors were concerned by the drug’s tendency to  slightly impair lung function. Alkermes Chairman Richard Pops, in an interview with  Reuters in October, said Air Insulin may have similar effects  on lung function. “We’re assuming that pulmonary insulins in that regard are  all pretty much the same,” he said, although a conclusive  picture of Air Insulin’s safety will not emerge until two-year  safety trials of the product end later this year. A second setback for inhaled insulin came in January, when  Novo Nordisk said it was halting development of its AERx  product, meant to deliver inhaled droplets. The Danish  drugmaker said AERx did not have adequate sales potential,  given the limited commercial success seen with Exubera. Morgan Stanley analyst Jami Rubin said on Friday Lilly’s  abandonment of AIR Insulin made good business sense. “We are not (at) all surprised, and have never been strong  advocates of the pulmonary insulin agents, following the poor  launch and ultimate demise of Pfizer and Nektar’s Exubera and  Novo Nordisk’s termination of its AERx program,” Rubin said in  a research note. Rubin said Alkermes, known for its drug-delivery  technology, is unlikely to continue development of Air Insulin  without Lilly, “given that this represents the third  termination of a pulmonary insulin drug.”    But she said the sharp drop in Alkermes shares represented  a buying opportunity for investors because Air Insulin had only  paltry sales potential. She said investors should be focused instead on another  product Alkermes is developing with Lilly: a long-acting  formulation of Lilly’s Byetta diabetes treatment called Byetta    “We estimate that Byetta LAR could be worth $11 to $12 for  the (Alkermes) stock,” Ryan said. Alkermes shares fell $1.14 to close at $11.26 on Nasdaq. Lilly, a far larger company with an array of big-selling  products, rose 2 cents to end at $49.70 on the New York Stock  Exchange, and was slightly lower at $49.67 in after-hours  trading.
Eli Lilly drops inhaled insulin program.

The experimental vaccine is being tested in an early-stage trial conducted by the U.S. National Institutes of Health and Moderna expects to begin mid-stage trial in the second quarter. Depending on the data from these studies and discussions with regulators, the company said a late-stage study could begin as soon as fall of 2020. The drug developer said BARDA funding would support the vaccine’s clinical development program, as well as the scale-up manufacture of the vaccine candidate, mRNA-1273, in 2020. Moderna plans to hire up to 150 new team members in the United States this year to support the ramp-up. Moderna’s study has made the most headway among efforts by the pharmaceutical industry to develop coronavirus vaccines as it is the first to be tested in human patients. The vaccine uses synthetic messenger RNA (mRNA) to inoculate against the coronavirus. Such treatments help the body immunize against a virus and can potentially be developed and manufactured more quickly than traditional vaccines.

Moderna receives $483 million BARDA award for COVID-19 vaccine development.